Report cover image

Lymphoma Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Publisher Fortune Business Insights Pvt. Ltd.
Published Jan 01, 2025
Length 125 Pages
SKU # FOB19847068

Description

Growth Factors of Lymphoma Treatment Market

The global lymphoma treatment market was valued at USD 6.94 billion in 2018 and is projected tsurpass USD 21.29 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.3% during the forecast period.

Key Market Drivers:
  • Increasing Prevalence of Lymphomas: A significant rise in lymphoma cases has heightened the demand for advanced treatment options. Many lymphomas remain asymptomatic until advanced stages, necessitating more aggressive therapies for effective outcomes.
  • Advancements in Research and Development: Leading biopharmaceutical companies are investing heavily in R&D tdevelop novel therapies. For instance, Kura Oncology's clinical trial of tipifarnib for peripheral T-cell lymphoma, which received FDA fast track designation in March 2020, exemplifies this trend.
Regional Insights:
  • North America: Dominated the market with a 47.98% share in 2018, attributed thigher lymphoma prevalence, greater patient awareness, and the adoption of advanced therapeutics.
  • Europe and Asia-Pacific: Europe is expected tmaintain a significant market share, while Asia-Pacific is projected texperience the highest CAGR during the forecast period, driven by approvals of key drugs and a large potential patient population.
Therapy Segmentation:
  • Immunotherapy: Accounted for the largest market share in 2018 due tits success in achieving positive outcomes. Products like Yescarta by Kite Pharma, Inc. have been instrumental in this segment's dominance.
  • Targeted Therapy and Chemotherapy: Targeted therapy holds the second-largest segment, owing tthe precision in targeting cancer cells. Chemotherapy remains a vital treatment option due tits established efficacy.
Challenges:
  • High Treatment Costs: In emerging regions, the high cost of therapies, especially immunotherapies, limits patient access and adoption, posing a significant challenge tmarket growth.
Overall, the lymphoma treatment market is poised for substantial growth, driven by increasing disease prevalence and continuous advancements in therapeutic options.

ATTRIBUTE DETAILS

Study Period - 2015-2026

Base Year - 2018

Forecast Period - 2019-2026

Historical Period - 2015-2017

Unit - Value (USD billion)

Segmentation By Therapy
  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Others
By Disease Type
  • Non-Hodgkin Lymphoma
  • Hodgkin Lymphoma
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies
By Geography
  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia-Pacific)
  • Latin America (Brazil, Mexico, and the Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and the Rest of Middle East & Africa)


Please Note: It will take 5-6 business days to complete the report upon order confirmation.

Table of Contents

125 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Prevalence of Lymphoma - by Key Countries - 2018
4.2. Pipeline Analysis
4.3. Key Industry Developments
4.4. Regulatory Scenario, by Key Regions
4.5. Analysis of Economic Burden of Lymphoma
4.6. New Product Launches
4.7. Overview of Emerging Treatments for Lymphoma
5. Global Lymphoma Treatment Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Therapy
5.2.1. Immunotherapy
5.2.2. Targeted Therapy
5.2.3. Chemotherapy
5.2.4. Others
5.3. Market Analysis, Insights and Forecast – By Disease Type
5.3.1. Non-Hodgkin Lymphoma
5.3.2. Hodgkin Lymphoma
5.4. Market Analysis, Insights and Forecast – By Distribution Channel
5.4.1. Hospital Pharmacies
5.4.2. Retail Pharmacies & Drug Stores
5.4.3. Online Pharmacies
5.5. Market Analysis, Insights and Forecast – By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia Pacific
5.5.4. Latin America
5.5.5. Middle East & Africa
6. North America Lymphoma Treatment Market Analysis, Insights and Forecast, 2015-2026
6.1. Key Findings / Summary
6.2. Market Analysis – By Therapy
6.2.1. Immunotherapy
6.2.2. Targeted Therapy
6.2.3. Chemotherapy
6.2.4. Others
6.3. Market Analysis – By Disease Type
6.3.1. Non-Hodgkin Lymphoma
6.3.2. Hodgkin Lymphoma
6.4. Market Analysis – By Distribution Channel
6.4.1. Hospital Pharmacies
6.4.2. Retail Pharmacies & Drug Stores
6.4.3. Online Pharmacies
6.5. Market Analysis – By Country
6.5.1. U.S.
6.5.2. Canada
7. Europe Lymphoma Treatment Market Analysis, Insights and Forecast, 2015-2026
7.1. Key Findings / Summary
7.2. Market Analysis – By Therapy
7.2.1. Immunotherapy
7.2.2. Targeted Therapy
7.2.3. Chemotherapy
7.2.4. Others
7.3. Market Analysis – By Disease Type
7.3.1. Non-Hodgkin Lymphoma
7.3.2. Hodgkin Lymphoma
7.4. Market Analysis – By Distribution Channel
7.4.1. Hospital Pharmacies
7.4.2. Retail Pharmacies & Drug Stores
7.4.3. Online Pharmacies
7.5. Market Analysis – By Country/ sub-region
7.5.1. U.K.
7.5.2. Germany
7.5.3. France
7.5.4. Spain
7.5.5. Italy
7.5.6. Scandinavia
7.5.7. Rest of Europe
8. Asia Pacific Lymphoma Treatment Market Analysis, Insights and Forecast, 2015-2026
8.1. Key Findings / Summary
8.2. Market Analysis – By Therapy
8.2.1. Immunotherapy
8.2.2. Targeted Therapy
8.2.3. Chemotherapy
8.2.4. Others
8.3. Market Analysis – By Disease Type
8.3.1. Non-Hodgkin Lymphoma
8.3.2. Hodgkin Lymphoma
8.4. Market Analysis – By Distribution Channel
8.4.1. Hospital Pharmacies
8.4.2. Retail Pharmacies & Drug Stores
8.4.3. Online Pharmacies
8.5. Market Analysis – By Country/ sub-region
8.5.1. Japan
8.5.2. China
8.5.3. India
8.5.4. Australia
8.5.5. Southeast Asia
8.5.6. Rest of Asia Pacific
9. Latin America Lymphoma Treatment Market Analysis, Insights and Forecast, 2015-2026
9.1. Key Findings / Summary
9.2. Market Analysis – By Therapy
9.2.1. Immunotherapy
9.2.2. Targeted Therapy
9.2.3. Chemotherapy
9.2.4. Others
9.3. Market Analysis – By Disease Type
9.3.1. Non-Hodgkin Lymphoma
9.3.2. Hodgkin Lymphoma
9.4. Market Analysis – By Distribution Channel
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies & Drug Stores
9.4.3. Online Pharmacies
9.5. Market Analysis – By Country/ sub-region
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
10. Middle East & Africa Lymphoma Treatment Market Analysis, Insights and Forecast, 2015-2026
10.1. Key Findings / Summary
10.2. Market Analysis – By Therapy
10.2.1. Immunotherapy
10.2.2. Targeted Therapy
10.2.3. Chemotherapy
10.2.4. Others
10.3. Market Analysis – By Disease Type
10.3.1. Non-Hodgkin Lymphoma
10.3.2. Hodgkin Lymphoma
10.4. Market Analysis – By Distribution Channel
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies & Drug Stores
10.4.3. Online Pharmacies
10.5. Market Analysis – By Country/ sub-region
10.5.1. GCC Countries
10.5.2. South Africa
10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
11.1. Key Industry Developments
11.2. Global Market Share Analysis (2018)
11.3. Competition Dashboard
11.4. Comparative Analysis – Major Players
11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
11.5.1. Takeda Pharmaceutical Company Limited
11.5.1.1. Overview,
11.5.1.2. Products & services,
11.5.1.3. SWOT analysis,
11.5.1.4. Recent developments,
11.5.1.5. strategies,
11.5.1.6. financials (based on availability)
11.5.2. AstraZeneca
11.5.2.1. Overview,
11.5.2.2. Products & services,
11.5.2.3. SWOT analysis,
11.5.2.4. Recent developments,
11.5.2.5. strategies,
11.5.2.6. financials (based on availability)
11.5.3. Bayer AG
11.5.3.1. Overview,
11.5.3.2. Products & services,
11.5.3.3. SWOT analysis,
11.5.3.4. Recent developments,
11.5.3.5. strategies,
11.5.3.6. financials (based on availability)
11.5.4. Novartis AG
11.5.4.1. Overview,
11.5.4.2. Products & services,
11.5.4.3. SWOT analysis,
11.5.4.4. Recent developments,
11.5.4.5. strategies,
11.5.4.6. financials (based on availability)
11.5.5. Spectrum Pharmaceuticals, Inc.
11.5.5.1. Overview,
11.5.5.2. Products & services,
11.5.5.3. SWOT analysis,
11.5.5.4. Recent developments,
11.5.5.5. strategies,
11.5.5.6. financials (based on availability)
11.5.6. Bristol Myers Squibb Company
11.5.6.1. Overview,
11.5.6.2. Products & services,
11.5.6.3. SWOT analysis,
11.5.6.4. Recent developments,
11.5.6.5. strategies,
11.5.6.6. financials (based on availability)
11.5.7. Janssen Pharmaceuticals, Inc.
11.5.7.1. Overview,
11.5.7.2. Products & services,
11.5.7.3. SWOT analysis,
11.5.7.4. Recent developments,
11.5.7.5. strategies,
11.5.7.6. financials (based on availability)
11.5.8. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
11.5.8.1. Overview,
11.5.8.2. Products & services,
11.5.8.3. SWOT analysis,
11.5.8.4. Recent developments,
11.5.8.5. strategies,
11.5.8.6. financials (based on availability)
11.5.9. Merck & Co., Inc.
11.5.9.1. Overview,
11.5.9.2. Products & services,
11.5.9.3. SWOT analysis,
11.5.9.4. Recent developments,
11.5.9.5. strategies,
11.5.9.6. financials (based on availability)
11.5.10. Spectrum Pharmaceuticals, Inc.
11.5.10.1. Overview,
11.5.10.2. Products & services,
11.5.10.3. SWOT analysis,
11.5.10.4. Recent developments,
11.5.10.5. strategies,
11.5.10.6. financials (based on availability)
11.5.11. Other Prominent Players
11.5.11.1. Overview,
11.5.11.2. Products & services,
11.5.11.3. SWOT analysis,
11.5.11.4. Recent developments,
11.5.11.5. strategies,
11.5.11.6. financials (based on availability)
12. Strategic Recommendations

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us